3种治疗下呼吸道感染方案的成本-效果分析  

The cost-effectiveness analysis of three therapeutic schemes for lower respiratory tract infections

作　　者：汪荣军[1] 安益国[1] 徐圣葆[2] 

机构地区：[1]安徽省立友谊医院药剂科,安徽合肥230011 [2]安徽省立友谊医院呼吸内科,安徽合肥230011

出　　处：《淮海医药》2006年第3期180-182,共3页Journal of Huaihai Medicine

摘　　要：目的评价下呼吸道感染的3种治疗方案所产生的药物经济学效果。方法采用回顾性研究方法,运用药物经济学成本-效果分析法(cost-effectiveness analysis,CEA)对头孢曲松钠治疗组(G1)、左氧氟沙星治疗组(G2)和阿奇霉素治疗组(G3)3种治疗方案进行分析。结果3组治疗方案有效率分别为76.65%、84.10%、88.56%;不良反应发生率分别为6.83%、12.01%、10.87%。平均成本-效果比分别为16.31%、17.74%、20.65%。结论G1组为较合理的治疗方案,G3组虽然成本高,但有效率也高,不良反应较少,有利于提高患者生命质量。Objective To evaluate the pharmacoeconomic effectiveness of three therapeutic schemes for lower respiratoy tract infections. Methods Principle of pharmacoeconomic cost-effectiveness analysis was adopted to analyze cost-effectiveness of the three treatment schemes of ceftriaxone treatment group （G1）, levofloxacin treatment group （G2） and azithromycin treatment group （G3） for lower respiratory tract infectlons. Results In G1, G2 and G3, the clinical effective rates were 76.65%, 84.10% and 88.56% respectively; adverse reaction （ADR） rates were 6.83%, 12.01% and 10.87% respectively; and the cost-effectiveness rates were 16.31%, 17.74% and 20.65% respectively. Conclusion G1 is the best therapeutic scheme. Although G3 scheme had higher cost, it had higher cure rate and lower ADR occurrence, G3 scheme is benefitial to the improvement of patient＇s life quality.

关 键 词：下呼吸道感染 治疗方案 药物经济学 成本-效果分析 

分 类 号：R956[医药卫生—药学]